Immunome, Inc. (NASDAQ:IMNM) Given Average Recommendation of “Buy” by Analysts
Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have covered the stock in the last year […]
Immunome, Inc. (NASDAQ:IMNM – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have covered the stock in the last year […]
